What is the risk of intracranial bleeding during anti-VEGF therapy?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neuro-Oncology

• Publication date

  2008-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1215/15228517-2008-010PMID 18539884PMCID PMC2666237
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

  2010cited by this paper
• Vascular targeted therapies in oncology

  2008cited by this paper
• Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.

  2007cited by this paper
• A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize

  2007cited by this paper
• The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses

  2007cited by this paper
• Chemotherapy delivery issues in central nervous system malignancy: a reality check.

  2007cited by this paper
• Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)

  2007cited by this paper
• Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

  2007cited by this paper
• Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.

  2007cited by this paper
• Mechanisms of adverse effects of anti-VEGF therapy for cancer

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM)

  2007cited by this paper
• Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

  2007cited by this paper
• CNS Metastasis: An Old Problem in a New Guise

  2007cited by this paper
• Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.

  2006cited by this paper
• Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.

  2006cited by this paper
• Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  2006cited by this paper
• Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma

  2006cited by this paper
• Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results.

  2006cited by this paper
• Tumor Vasculature: a Target for Anticancer Therapies

  2006cited by this paper
• A phase II study of high-dose bevacizumab in combination with irinotecan , 5-fluorouracil , leucovorin , as initial therapy for advanced colorectal cancer : results from the eastern cooperative oncology group study E 2200

  2006cited by this paper
• Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

  2006cited by this paper
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.

  2006cited by this paper
• Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

  2006cited by this paper
• A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

  2006cited by this paper
• Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

  2006cited by this paper
• Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients

  2006cited by this paper
• Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents.

  2006cited by this paper
• A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

  2006cited by this paper
• Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

  2006cited by this paper
• Phase I/Pilot Study of SU5416 (Semaxinib) in Combination With Irinotecan/Bolus 5-FU/LV (IFL) in Patients With Metastatic Colorectal Cancer

  2006cited by this paper
• A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.

  2006cited by this paper
• Sunitinib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

  2005cited by this paper
• A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck

  2005cited by this paper
• Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

  2005cited by this paper
• A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points

  2005cited by this paper
• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

  2005cited by this paper
• Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

  2005cited by this paper
• Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

  2005cited by this paper
• Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

  2005cited by this paper
• A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

  2005cited by this paper
• Current management of brain metastases, with a focus on systemic options.

  2005cited by this paper
• Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

  2005cited by this paper
• Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

  2005cited by this paper
• Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.

  2005cited by this paper
• Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

  2005cited by this paper
• Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

  2005cited by this paper
• Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

  2005cited by this paper
• Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

  2005cited by this paper
• Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

  2005cited by this paper
• Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

  2005cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU 5416 in Advanced Melanoma

  2004cited by this paper
• Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma

  2004cited by this paper
• A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM).

  2004cited by this paper
• A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer

  2004cited by this paper
• Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas

  2004cited by this paper
• A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma

  2004cited by this paper
• A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM).

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

  2003cited by this paper
• Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

  2003cited by this paper
• SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.

  2003cited by this paper
• Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

  2002cited by this paper
• Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.

  2002cited by this paper
• Long-term survival in patients with brain metastases

  2002cited by this paper
• Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

  2001cited by this paper
• Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases.

  2000cited by this paper
• Incidence and treatment of peripheral venous thrombosis in patients with glioma

  1983cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper

• Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity

  2025cites this paper
• Brain hemorrhage in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports

  2025cites this paper
• Screening of novel alkaloid inhibitors for vascular endothelial growth factor in cancer cells: an integrated computational approach

  2021cites this paper
• Neurologic Complications in Patients with Cancer

  2021cites this paper
• Supportive Medical Management of Brain Metastases Patients Including Treatment Complications

  2020cites this paper
• Neurologic Complications

  2020cites this paper
• Management of patients suffering from hemorrhagic intracranial metastases: Propositions to help the neurosurgeon in emergencies situations based on a literature review.

  2020cites this paper
• A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma

  2020cites this paper
• Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases

  2019cites this paper
• Operative and peri‐operative considerations in the management of brain metastasis

  2019cites this paper
• Seizures in Patients With Metastatic Brain Tumors: Prevalence, Clinical Characteristics, and Features on EEG.

  2019cites this paper
• Intracranial Bleeding during Treatment with Sorafenib for Hepatocellular Carcinoma

  2019cites this paper
• Metastatic Surgery in Advanced Renal Cell Carcinoma

  2019cites this paper
• Neurological complications of lung cancer

  2018cites this paper
• Neurologic Complications of Systemic Anticancer Therapy.

  2018cites this paper
• Management of the toxicities of common targeted therapeutics for gynecologic cancers.

  2018cites this paper
• Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab

  2017cites this paper
• Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis

  2017influential citation
• Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.

  2017cites this paper
• Chapter 28 – Overview

  2017cites this paper
• Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage.

  2017cites this paper
• Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy.

  2016cites this paper
• Central Nervous System Complications of Oncologic Therapy.

  2016cites this paper
• Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis

  2016cites this paper
• Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature.

  2016cites this paper
• Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer.

  2016cites this paper
• Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy

  2016cites this paper
• Brain Metastasis and Intracranial Hemorrhage Following Bevacizumab Therapy for Rhabdomyosarcoma

  2016cites this paper
• Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis.

  2015cites this paper
• Remote multiple intracranial hemorrhage in multiple metastatic lung adenocarcinoma following decompression of posterior fossa lesion: Unknown cause

  2015cites this paper
• The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives.

  2014cites this paper
• Extending survival of stage IV non-small cell lung cancer.

  2014cites this paper
• Targeting Angiogenesis, Enhancing Radiosensitization and Crossing the Blood–Brain Barrier for Brain Metastases

  2014cites this paper
• Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis

  2014cites this paper
• Neurologic complications of chemotherapy and other newer and experimental approaches.

  2014cites this paper
• Diffusion restriction in a non-enhancing metastatic brain tumor treated with bevacizumab - recurrent tumor or atypical necrosis?

  2014cites this paper
• Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

  2013cites this paper
• Biology of brain metastases and novel targeted therapies: time to translate the research.

  2013cites this paper
• Clinical discussion and review of the management of brain metastases.

  2013cites this paper
• Safety of bevacizumab in patients with malignant gliomas: a systematic review

  2013cites this paper
• Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review).

  2013cites this paper
• Bevacizumab and central nervous system (CNS) hemorrhage

  2013cites this paper
• Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2013cites this paper
• An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases.

  2012cites this paper
• The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients

  2012cites this paper
• Antiangiogéniques et métastases cérébrales: plus de peur que de mal ?

  2012influential citation
• Neurotoxicity of biologically targeted agents in pediatric cancer trials.

  2012cites this paper
• Imaging Findings in Cancer Therapy-Associated Neurotoxicity

  2012cites this paper
• Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: A case series study

  2012cites this paper
• [Renal carcinoma: point on treatment of brain metastasis].

  2012cites this paper
• An overview of angiogenesis and renal cell carcinoma

  2012cites this paper
• MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.

  2012cites this paper
• Brain metastases from renal cell carcinoma. Should we change the current standard?

  2012cites this paper
• Novel agents in renal carcinoma: a reality check

  2012influential citation
• Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience.

  2012cites this paper
• Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead

  2012cites this paper
• Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review.

  2011cites this paper
• Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.

  2011cites this paper
• Angiogenesis and Brain Tumors

  2011cites this paper
• Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

  2011cites this paper
• Revisiting the role of molecular targeted therapies in patients with brain metastases

  2011cites this paper
• Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy

  2011cites this paper
• Intracranial hemorrhage in patients treated with bevacizumab: report of two cases.

  2011cites this paper
• Bp5250 inhibits vascular endothelial growth factor-induced angiogenesis and HIF-1α expression on endothelial cells

  2011cites this paper
• Risque hémorragique et anti-angiogéniques

  2010cites this paper
• Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer

  2010cites this paper
• Pretruncal subarachnoid hemorrhage and high cerebral blood flow velocities with bevacizumab therapy.

  2010cites this paper
• Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

  2010cites this paper
• [Anti-angiogenic therapies and hemorrhagic risk].

  2010cites this paper
• Headache in Patients with Cancer

  2010cites this paper
• [Advanced renal carcinomas with special situations. How to treat them?].

  2010cites this paper
• Neurological complications of systemic cancer.

  2010cites this paper
• Cancers du rein avancés en situations particulières. Comment les traiter

  2010cites this paper
• Bevacizumab Safety in Patients with Central Nervous System Metastases

  2009cites this paper
• Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.

  2009cites this paper
• Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

  2009cites this paper
• Neurological adverse effects caused by cytotoxic and targeted therapies

  2009cites this paper
• Eligibility of patients with brain metastases for phase I trials: time for a rethink?

  2008cites this paper
• Neurotoxicity of Cancer Chemotherapy

  2004cites this paper